STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
An experimental Novartis drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study
STAT
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from STAT.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
From the CurrentWire archive
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
STAT (www.statnews.com), a Tier B publisher, filed this report on . CurrentWire published this page 3 minutes later, on .
Signal breakdown
CurrentWire ranked this story 62.9 of 100 in the snapshot this page was rendered from.
- Freshness
- 33.4 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 33.4 of 35. How each signal is calculated.
Filed under Health · International · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Novo Nordisk (1).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.